Skip to Main Content

Stephanie Prozora, MD

Assistant Professor of Clinical Pediatrics (Hematology/Oncology); Pediatric Medical Director, Yale Hemophilia Treatment Center, Pediatrics

Contact Information

Stephanie Prozora, MD

Mailing Address

  • Pediatric Hematology & Oncology

    PO Box 208064

    New Haven, CT 06520-8064

    United States

Research Summary

My primary research goal is to improve the quality of life of pediatric hematology and oncology patients. I have several ongoing health services projects focused on palliative and end-of life care for pediatric cancer patients. As part of the Hemophilia Treatment Center, I am also conducting clinical and quality improvement research in our patients with bleeding and clotting disorders.

Coauthors

Research Interests

Hemophilia B; Education; Hemophilia A; Palliative Care; Quality of Life; Hematologic Neoplasms; Thrombophilia; Quality Improvement

Selected Publications

Clinical Trials

ConditionsStudy Title
Brain and Nervous SystemA Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
PediatricsA Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations
Brain and Nervous System; PediatricsA Target Validation/Phase1 Study of BGB-290 in Combination With Temozolomide in Adolescent and Young Adult IDH1/2 Newly Diagnosed and Recurrent Mutant Gliomas
Leukemia, not otherwise specified; Leukemia, other; PediatricsA Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Bones and Joints; Kidney; Soft Tissue; PediatricsPhase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumors
Soft TissueA Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma
Lymphoid LeukemiaA Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia
Other Male Genital; OvaryActive Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
Bones and Joints; Brain and Nervous System; Eye and Orbit; Hodgkin's Lymphoma; Kidney; Leukemia, other; Liver; Lymphoid Leukemia; Myeloid and Monocytic Leukemia; Non-Hodgkin's Lymphoma; Other Digestive Organ; Other Endocrine System; Other Female Genital; Other Male Genital; Other Respiratory and Intrathoracic Organs; Other Skin; Other Urinary; Ovary; Small Intestine; Soft Tissue; PediatricsThe Project: Every Child Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
Other Respiratory and Intrathoracic Organs; PediatricsEffects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment (HEART)